Understanding the Setup: (NRC) and Scalable Risk
This article analyzes National Research Corporation (NYSE: NRC), highlighting strong sentiment across all horizons and an exceptional 67.2:1 risk-reward setup targeting a 19.3% gain. It details three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored to different risk profiles and holding periods, along with multi-timeframe signal analysis indicating strong support and resistance levels. The report emphasizes the current AI signals, entry/exit points, and risk management parameters for NRC.
TradingKey
This page provides an overview of National Research Corp (NRC) stock on the TradingKey platform. It displays real-time stock data, including its current price, daily change, market cap, and P/E ratio. The article also outlines various sections available for the stock, such as Financials, Discussions, and Analysis.
National Research (NRC) 10K Form and Latest SEC Filings 2026
MarketBeat provides comprehensive information on National Research (NRC)'s SEC filings, highlighting that the company has submitted over 397 documents since 2017. These filings are critical for investors to access verified financial data, including annual 10-K reports, quarterly 10-Q reports, and 8-K current reports. The article details the most recent filings and explains the significance of various SEC document types for investment analysis.
Redwood AI Approved to Receive National Research Council of Canada Funding for its Q-SAFE Chemical Screening Project for Defence and Security Applications
Redwood AI's subsidiary has been approved to receive up to C$240,000 in funding from the National Research Council of Canada's Industrial Research Assistance Program for its Q-SAFE project. This initiative focuses on improving hazardous chemical risk classification using AI and quantum-enhanced optimization, with applications in defense, security, and industrial settings. The project aims to enhance chemical data analysis for safer and more reliable screening of hazardous materials, supporting both commercial and public-sector needs.
Outstanding NRC Patient Experience Scores Rank Sanford Bismarck Therapy Team Among Nation’s Best
The therapy team at Sanford Health in Bismarck has achieved exceptional 2025 year-end patient experience results from the National Research Corporation (NRC), ranking among the nation's best. They scored in the 100th percentile for "Staff listens" and high percentiles for "Staff explains" and "Had enough input," reflecting their commitment to compassionate, patient-centered care. These scores highlight the team's dedication to creating a supportive environment where patients feel heard and involved in their care decisions.
National Research (NASDAQ:NRC) Stock Price Crosses Above 200 Day Moving Average - What's Next?
Shares of National Research Corporation (NASDAQ:NRC) crossed above its 200-day moving average on Tuesday, trading as high as $19.31 with a volume of 132,991 shares. The company recently announced a quarterly dividend of $0.16 per share, payable on July 10th to shareholders of record on June 26th, representing an annualized yield of 3.4%. While institutional investors have been adjusting their stakes in NRC, one analyst recently downgraded the stock from "hold" to "sell."
Earnings call transcript: NRC Health Q1 2026 sees growth but cautious market
NRC Health reported its Q1 2026 earnings, showcasing a return to revenue growth for the first time since 2023, with a 4% year-over-year increase to $34.8 million and an EPS of $0.21. The Total Recurring Contract Value (TRCV) reached a record high of $152.1 million, driven by strong sales bookings and an unprecedented landmark deal. Despite these positive financial results and a 60.7% return over the past year, the stock price experienced a slight decline of 1.23% in aftermarket trading, reflecting a cautious investor sentiment. The company anticipates flat adjusted EBITDA margins in Q2 2026 due to implementation costs for the new deal, with expansion expected in Q3 2026.
NRC Health (NRC) Q1 2026 Earnings: GAAP EPS $0.14, Revenue $34.8M -- Is the Stock 26.3% Undervalued?
NRC Health (NRC) reported strong Q1 2026 earnings, with revenue up 4% year-over-year to $34.8 million and GAAP EPS at $0.14. The company achieved a record Total Recurring Contract Value (TRCV) of $152.1 million, reflecting healthy commercial momentum and client engagement. GuruFocus assesses NRC Health as 26.3% undervalued based on its GF Value, with a GF Score of 73/100, indicating above-average potential.
National Research (NASDAQ:NRC) Releases Quarterly Earnings Results
National Research (NASDAQ:NRC) recently announced its quarterly earnings, reporting $0.14 EPS. The company showed strong profitability with a 103.84% return on equity and an 8.44% net margin. Despite positive profitability metrics, the stock experienced a slight dip, trading at $16.88, and received a "Sell" rating from analysts and Weiss Ratings due to weak investor sentiment.
National Research: Q1 Earnings Snapshot
National Research Corp. (NRC) reported a net income of $3.2 million in its first quarter, with earnings of 14 cents per share. Adjusted for non-recurring costs, the company's earnings were 21 cents per share. The healthcare advisor also posted revenue of $34.8 million for the period.
NRC Health lands biggest deal in 45 years as revenue growth returns
NRC Health reported a strong first quarter for 2026, with total revenue rising 4% year-over-year to $34.8 million and Total Recurring Contract Value (TRCV) increasing 13% to $152.1 million. The company secured its largest deal in 45 years, indicating significant momentum and strategic validation. NRC Health also declared a quarterly cash dividend of $0.16 per share, payable on July 10, 2026.
National Research (NASDAQ:NRC) Stock Crosses Above 200 Day Moving Average - Time to Sell?
National Research (NASDAQ:NRC) stock has recently crossed above its 200-day moving average of $16.45, trading as high as $17.60 before settling at $17.11 with a volume of 112,562 shares. Despite this upward movement, Weiss Ratings downgraded the stock to "sell (d+)," and MarketBeat's consensus rating is also "Sell," citing weak liquidity (current and quick ratios 0.55), high leverage (debt-to-equity 5.36), and a P/E of 34.2, even though ROE was 103.8%. Institutional investors have shown mixed activity, with some increasing their stakes while others have remained stable.
70% of hospital boards lack continuing education, NRC report says
A new report by The Governance Institute (TGI), a service of NRC Health, titled "Falling Behind," indicates that hospital governance models are lagging behind the advancements in modern healthcare. The report, released during TGI's 250th Leadership Conference, highlights that roughly 70% of hospital boards lack continuing education requirements and suggests that only a tiny fraction of hospital patient revenue is invested in board development. TGI is introducing a "Governance Trilogy" and forming a Blue-Ribbon Committee to address these gaps and redesign healthcare governance.
NRC Health (Nasdaq:NRC) - Stock Analysis
This report provides a stock analysis of NRC Health (Nasdaq:NRC), highlighting its current market capitalization of US$390.8m and a stock price of US$17.50. The analysis points out that the company is 107.8% overvalued based on fair value estimates and notes risks such as declining earnings, poorly covered dividends, and changes in profit margins. It also includes recent news, performance summaries, and an overview of the company's fundamentals and analyst coverage.
Precision Trading with National Research Corporation (NRC) Risk Zones
Quantitative Research Desk and Thomas H. Kee Jr. provide a detailed analysis of National Research Corporation (NYSE: NRC), highlighting strong sentiment and an exceptional 66.6:1 risk-reward setup. The analysis outlines three institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones, supported by multi-timeframe signal analysis.
National Research NRC Q4 2025 Earnings Transcript
National Research (NRC) reported its Q4 and full-year 2025 earnings, showing sequential revenue and Total Recurring Contract Value (TRCV) growth despite a challenging prior year. The company highlighted 99% recurring revenue, a record-high gross dollar retention rate, and significant growth in new sales following a restructured sales approach. Investments in AI-powered features and strategic leadership appointments are expected to drive future growth.
National Research NRC Q4 2025 Earnings Transcript
National Research Corporation (NRC) reported sequential revenue and Total Recurring Contract Value (TRCV) growth in Q4 2025 despite a challenging prior year. The company saw 99% recurring revenue, strong sales growth, and high customer retention, driven by restructured go-to-market strategies and product innovation, including AI-powered features. Management emphasizes continued growth, profitability, and strategic capital allocation for 2026, aiming for margin expansion as revenue recovers.
National Research Corp Changes Corporate Name To NRC Health
National Research Corp has officially changed its corporate name to NRC Health. This concise report, sourced from Reuters and Refinitiv, indicates a rebranding effort for the company.
NRC Health changes corporate name and declassifies board of directors
NRC Health has officially changed its corporate name from National Research Corporation to NRC Health and declassified its board of directors. The name change became effective on April 15, while the board declassification means all directors will now serve one-year terms and be subject to annual election. These changes, detailed in a recent SEC filing, are part of the company's corporate governance updates, alongside recent financial news including a decline in Q4 2025 revenue but strong recurring contract value and a new stock repurchase program.
NRC Health Adopts New Name and Governance Structure
National Research Corporation has legally rebranded as NRC Health, aligning its corporate name with its long-standing market identity while retaining its NASDAQ symbol "NRC". Alongside the name change, the company adopted new bylaws to modernize its governance structure, including declassifying its board of directors for annual elections and setting limits on board size. TipRanks' AI Analyst, Spark, rates NRC as Neutral due to financial performance concerns, though offset by positive free cash flow, a dividend yield, and record recurring contract value growth.
NRC Health (NASDAQ: NRC) declassifies board and formalizes new name
NRC Health (NASDAQ: NRC) has officially changed its legal name from National Research Corporation to NRC Health and declassified its Board of Directors. This change means all seven directors will stand for election annually, starting at the June 23, 2026 Annual Meeting, with existing directors whose terms extend beyond this date resigning to facilitate the new structure. Additionally, the company's bylaws were amended to cap the board at 12 directors and formalize the Chair's role, and an equity award for CFO Shane Harrison was modified to include voting and dividend rights on unvested restricted shares.
Clear Blue Technologies Receives $500K Grant Payment from National Research Council Canada
Clear Blue Technologies International Inc. announced it has received a $500,000 payment from the National Research Council Canada, Clean Technology Program. This final installment completes the original $5.0 million non-dilutive grant, marking the successful commercialization of its Pico product line and reinforcing the company's strategy for funding R&D and growth through non-dilutive means.
NRC Health Surges 62% in a Year: Should You Buy the Stock?
NRC Health has seen its shares surge by 61.8% over the past year, significantly outperforming its industry and competitors like Iron Mountain and Recruit Holdings. This growth is attributed to strong recurring revenues, high retention rates, the increasing adoption of its AI-enabled platform, and cross-selling opportunities within a healthcare industry shift towards value-based care. Despite facing competition, contract renewal risks, and operational challenges, the company's strong fundamentals and undervalued valuation suggest a lucrative investment opportunity.
Technical Reactions to NRC Trends in Macro Strategies
This article analyzes National Research Corporation (NYSE: NRC) using AI models, highlighting a weak near-term sentiment but strong long-term outlook. It presents three trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis and current support/resistance levels. The analysis suggests choppy conditions are likely due to divergent sentiment across different time horizons.
Chicago children's hospital adds NRC tool to track online reviews
Ann & Robert H. Lurie Children’s Hospital of Chicago has expanded its partnership with NRC Health to include NRC Health’s Reputation solution. This new tool will provide real-time visibility into the hospital's online presence and consumer perception, complementing their existing Market Insights and Patient Experience solutions. The expansion aims to integrate community perception, patient experience, and digital reputation for a more unified and actionable strategy in healthcare.
National Research (NASDAQ:NRC) Share Price Passes Above Two Hundred Day Moving Average - What's Next?
National Research (NASDAQ:NRC) saw its share price trade above its 200-day moving average, reaching $17.59 before settling at $17.34. Despite this, analyst sentiment remains negative, with a "Sell" rating and a recent downgrade from Weiss Ratings. Concerns about the company's financial health include a high dividend payout ratio, weak liquidity, and significant leverage.
National Research (NASDAQ:NRC) Breaks Key Trendline Amid Nasdaq Index Momentum
National Research (NASDAQ:NRC) is gaining attention as its share price has crossed key levels, driven by both institutional investment activity and its strong position in healthcare analytics within the broader Nasdaq index trends. The article indicates that NRC's valuation is influenced by operational performance and healthcare technology, while its stock movement reflects healthcare sector trends and the adoption of its analytics platform.
National Research Corp (NRC) Stock Price Quote Today & Current Price Chart
This article provides the current stock price quote and chart for National Research Corp (NRC). It also mentions that online trading is available through the Smart Investment App offered by Capital.com.
National Research Corp (NRC) Stock Price Quote Today & Current Price Chart
This article provides the stock price quote and current price chart for National Research Corp (NRC). It also mentions that Capital.com offers online trading with a smart investment app. The content is very minimal, essentially just stating what is being offered.
National Research Corp (NRC) Stock Price Quote Today & Current Price Chart
This page provides the current stock price quote and chart for National Research Corp (NRC). It also mentions that the content is provided by Capital.com, an online trading platform.
National Research Corp (NRC) Stock Price Quote Today & Current Price Chart | Capital.com Australia
This page on Capital.com Australia provides current trading information for National Research Corp (NRC) stock as a Contract for Difference (CFD). It details trading conditions, key financial stats like previous close, open, and 1-year change, and lists related articles and market reviews. The platform highlights the high-risk nature of CFD trading.
National Research Corporation (NASDAQ:NRC) Plans $0.16 Quarterly Dividend
National Research Corporation (NASDAQ:NRC) announced a quarterly dividend of $0.16 per share, payable on April 10th to shareholders of record on March 27th, with an ex-dividend date of March 27th. This dividend represents an annual yield of 3.7%, though the company's dividend growth has been modest at 0.2% annually over the past three years. The healthcare analytics firm reported recent quarterly EPS of $0.16 on $35.19 million in revenue, trading near a market cap of $396.8 million.
If You Invested $1,000 in National Resh Corp (NRC)
This article analyzes the historical performance of investing $1,000 in National Research Corporation (NRC) over various periods, showing returns for one, five, and ten years. It also provides a detailed overview of NRC Health, highlighting its focus on healthcare experience improvement, market research, and financial reporting. The analysis includes year-by-year stock performance comparisons against the S&P 500 and answers frequently asked questions about NRC investments.
Piedmont Names NRC Health as a Strategic Experience Partner to Support Mission-Driven Growth
Piedmont, a Georgia-based healthcare system serving 4.5 million patients annually across 27 hospitals and 2,000 locations, has partnered with NRC Health as its strategic experience management partner. This collaboration aims to enhance patient, family, employee, and consumer experiences by leveraging NRC Health's Patient Experience, Leader Rounding, and Market Insights solutions, alongside consulting services. The partnership seeks to unify experience data, strengthen caregiver engagement, and integrate patient feedback into strategic decisions.
National Research (NASDAQ:NRC) Trading Move Aligns With Nasdaq Index Fund
National Research Corporation (NASDAQ:NRC) has garnered market attention after its stock moved above a significant long-term moving average, indicating a shift in trading momentum. This positive movement, coupled with institutional activity and the company's healthcare analytics positioning, aligns with current Nasdaq index fund trends. The company uses cloud-based platforms to gather patient and workforce experience data for healthcare providers.
NRC (NRC) EVP Jason Rau granted 60,000 restricted stock units
Jason Rau, Executive Vice President at National Research Corp (NRC), was granted 60,000 restricted shares of common stock as part of the company's 2025 Omnibus Incentive Plan. These shares were awarded at no cash cost and will vest in three equal installments on January 1, 2027, 2028, and 2029. This transaction is a compensation-related equity grant rather than an open-market purchase, and following the award, Rau directly holds 60,000 shares.
What Makes National Research Corporation (NRC) a Good Investment Choice?
Long Cast Advisers, an investment firm, highlighted National Research Corporation (NASDAQ: NRC) in its Q4 2025 investor letter, noting it as a new position and a significant contributor. Despite the firm's reservations about the healthcare consulting business model, they see value in NRC's financial metrics, including its $430 million market capitalization and 13x multiple against annualized EBITDA. The article also mentions NRC's recent strong stock performance, with a 36.59% one-month return and an 11.26% gain over the past 52 weeks.
NRC SEC Filings - National Resh Corp 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for National Research Corporation (NRC) SEC filings, including 10-K, 10-Q, 8-K forms, and insider trading information. It highlights recent filings with AI-generated summaries, such as executive stock grants, option exercises, and the latest quarterly earnings report for Q3 2025. The platform aims to simplify access and understanding of regulatory documents for investors.
NRC SEC Filings - National Resh Corp 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for National Research Corporation (NRC) SEC filings, including 10-K, 10-Q, and 8-K forms, with AI-powered summaries. Recent filings highlight the appointment of a new CFO with details on compensation and the Q2-25 10-Q report, which revealed a significant profit decline, increased leverage, and changes in leadership. The platform aims to simplify the understanding of these regulatory documents for investors and traders.
National Research Shares Cross 200-Day Average, Analysts Warn of Sell Signal
Shares of National Research Corporation (NASDAQ:NRC), a healthcare analytics firm, have crossed above their 200-day moving average, a technical indicator that some analysts view as a potential sell signal. One analyst has downgraded the stock to a 'sell' rating due to valuation and performance concerns, despite the 200-day moving average typically being seen as a bullish signal. The stock's current trading at $14.97, along with its P/E ratio of 29.94 and high debt-to-equity ratio of 5.36, contribute to these concerns.
National Research (NASDAQ:NRC) Shares Pass Above 200 Day Moving Average - Time to Sell?
National Research (NASDAQ:NRC) shares recently crossed above their 200-day moving average, trading as high as $15.92, though they closed at $14.97. Despite this, Weiss Ratings downgraded the stock to "sell" due to concerns about its financial health, including a high payout ratio of 128%, weak liquidity, and significant debt. Institutional investors have made varied adjustments to their holdings in NRC, which operates as NRC Health, specializing in healthcare analytics.
National Research Hits Record Recurring Contract Value Milestone
NRC Health reported a record Total Recurring Contract Value (RCV) of over $152 million, marking a 6% increase from the end of 2025 and 13% year-over-year growth. Despite this milestone, TipRanks' AI Analyst, Spark, rates NRC as Neutral, citing deteriorating financial performance, elevated leverage, and bearish technicals. NRC Health is a healthcare technology company providing solutions to improve healthcare experience.
National Research Corporation (NRC) Approves $60 Million Stock B
National Research Corporation (NRC) has approved a stock repurchase program of up to $60 million, aiming to enhance shareholder value through March 31, 2028. The company, which provides healthcare analytics, exhibits strong gross margins but faces challenges with a high debt-to-equity ratio and potential liquidity issues. Despite a premium valuation and high volatility, insider activity shows positive sentiment, and the buyback is expected to provide a short-term boost.
NRC falls after announcing $60 million share repurchase program
NRC Group Holdings Inc. stock fell after the company announced a $60 million share repurchase program. The repurchases will be made using available cash and cash generated from operations, and will occur at management's discretion. The program does not obligate the company to acquire any specific number of shares.
Healthcare data firm NRC Health earmarks $60M to buy back stock
NRC Health (NASDAQ: NRC) announced that its Board of Directors has authorized a share repurchase program of up to $60 million of its common stock, effective through March 31, 2028. The company plans to repurchase shares through various means, including open market and privately negotiated transactions, in compliance with SEC regulations. This move aims to return value to shareholders and will be executed at NRC Health's discretion based on market conditions and other factors.
National Research Corporation announces an Equity Buyback for $60 million worth of its shares.
National Research Corporation (NRC) has authorized a share repurchase program worth up to $60 million. This program will be active until March 31, 2028, allowing the company to buy back its own shares from the market. The announcement was made on March 9, 2026.
Price-Driven Insight from (NRC) for Rule-Based Strategy
This article provides a price-driven insight for National Research Corporation (NYSE: NRC), highlighting strong sentiment across all horizons and a mid-channel oscillation pattern. It presents an exceptional risk-reward short setup and outlines three distinct AI-generated trading strategies tailored for different risk profiles: a position trading strategy, a momentum breakout strategy, and a risk hedging strategy, complete with entry, target, and stop-loss levels.
National Research Corporation (NRC) Hits Record High in Recurring Contract Value
National Research Corporation (NRC) has achieved a record Total Recurring Contract Value (TRCV) exceeding $152 million as of March 4, 2026. Despite this milestone, the company faces financial challenges including modest revenue growth, declining profitability, and high debt levels, leading to potential liquidity concerns. While the stock appears to trade at a premium, investors are advised to exercise cautious optimism due to mixed financial indicators and various risk factors.
National Research 2025 10-K: Revenue $137.4M, EPS $0.50
National Research (NRC) reported 2025 revenues of $137.4 million and diluted EPS of $0.50, both declining from 2024 due to reduced recurring revenue from existing customers. Despite a fall in operating and net income, the company anticipates a recovery in revenue and cash generation for 2026, driven by operational initiatives and new product launches.
National Research Corporation (NRC) Hits Record High in Recurring Contract Value
National Research Corporation (NRC) has achieved a record-high Total Recurring Contract Value (TRCV) of over $152 million, indicating expected revenue from renewable contracts. Despite this milestone, the company faces financial challenges including modest revenue growth, declining operating margins, high debt, and potential liquidity concerns, placing it in a "grey area" for financial stress. Investors are advised to exercise cautious optimism due to mixed financial indicators and various risk factors.
